Therapeutic Evaluation of Intralesional 5% 5‐Fluorouracil in Condyloma Acuminata

Condyloma acumianata is one of the most common virally transmitted diseases. Its prevalence has increased many fold throughout the world. Because all the currently available treatments yield low cure rates with side effects, the search for a new alternative continues. Topically, 5‐fluorouracil (5‐FU...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2004-04, Vol.31 (4), p.314-325
Main Authors: Pall, Anuj, Mahajan, Bharat Bhushan, Puri, Karanjit Pal Singh, Gupta, Rajesh Rani
Format: Article
Language:English
Subjects:
5‐fluorouracil
Adolescent
Adult
Aged
Antimetabolites, Antineoplastic - administration & dosage
condyloma acuminata
Condylomata Acuminata - drug therapy
Condylomata Acuminata - pathology
Female
Fluorouracil - administration & dosage
Genital Diseases, Female - drug therapy
Genital Diseases, Female - pathology
Genital Diseases, Male - drug therapy
Genital Diseases, Male - pathology
Humans
Injections, Intralesional
intralesional
Male
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Condyloma acumianata is one of the most common virally transmitted diseases. Its prevalence has increased many fold throughout the world. Because all the currently available treatments yield low cure rates with side effects, the search for a new alternative continues. Topically, 5‐fluorouracil (5‐FU) has been in used for many years to treat various skin diseases. When applied topically in condyloma acuminata, 5‐FU results in low cure rates with high recurrences. Therefore, intralesional 5% 5‐FU is being evaluated to determine its therapeutic efficacy in condyloma acuminata.
ISSN:0385-2407
1346-8138
DOI:10.1111/j.1346-8138.2004.tb00678.x